Sixteen months after it emerged from stealth, Trucode has moved on from gene editing and relaunched as Vera with an Abingworth-led $80 million series C round to build an in-licensed portfolio of autoimmune assets. First up for the...

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on July 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope...

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which...

Abac Therapeutics S.A. is taking a precision approach to treat bacterial infections that could avoid the development of drug resistance that plagues broad-spectrum antibiotics. The company’s PasNas platform uses phenotypic and in vitro assays to...

Despite the tremendous public health need and the introduction of regulatory incentives including expedited review and market exclusivity, venture investing in antibiotics remains modest and focused primarily on clinical assets seeking to improve on known...

Visterra Inc. (Cambridge, Mass.) reported preclinical data from mouse models of primary and secondary dengue fever infection showing that VIS513 significantly reduced viral titers vs. controls and protected mice from lethal infections. Data were published...

On Oct. 18, Vir Biotechnology Inc. (San Francisco, Calif.) revealed a crop of new deals and said it has raised more than $500 million to date. CEO George Scangos told BioCentury the company's current round...